AdvanCellSenior Translational Scientist
Translational Research Institute, Brisbane, QLD, AU · Full-time
Series D · $315M · 106d ago Posted 2d ago
Have your AI draft the answers and brief you on AdvanCell→Why join AdvanCell?
Radiation that reaches only the tumor becomes the default cancer treatment, and older therapies start to look dated. AdvanCell, a Sydney radiopharmaceutical developer, is building that with targeted alpha therapies, and owning both development and manufacturing could make it a supplier drug makers rely on. Eli Lilly and Bain Capital Life Sciences sit among the leads on a $315M Series D, bringing its total to $453M across 5 rounds.
JustBacked's take, based on AdvanCell's own site and its funding and hiring data.
The Senior Translational Scientist will manage and conduct advanced preclinical studies, playing a key role in the development of innovative therapeutics. They will design, organise and execute in vitro, ex-vivo, and in vivo assays, including target expression analysis, cytotoxic assays, radioligand-binding assays, and biodistribution, toxicity and efficacy studies in animal models. The Senior Translational Scientist will also be responsible for training and mentoring researchers, leading cross-functional collaborations, and play a prominent role in project management. The ideal candidate will possess strong in vitro and in vivo technical skills, experience in preclinical imaging and data analysis expertise, contributing to project success through accurate reporting and communication with internal teams and external partners.